Please assess the completion status of the following clinical trial:

Trial Title: Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Participant was \>20 years and \<75 years of age on the index date (i.e., the date of initiating MK-0954A therapy)~* Diagnosed with hypertension and had received MK-0954A 50/12.5 mg for at least 3 months~* Had at least one serum uric acid measurements at baseline and one at 3 months after using MK-0954A 50/12.5 mg~* Had the following records documented in the chart during the data collection period:~  * medical history and co-morbidities (if available)~ * sitting blood pressure, serum uric acid, lipid profile test results before and after using MK-0954A 50/12.5 mg~ * serum electrolytes, serum creatinine, and pre-meal sugar (if available)~ * prescription information of all antihypertensive regimens~Exclusion criteria:~* Had been treated with diuretic or angiotensin-receptor blockers (ARBs) 2 weeks before initiated treatment with MK-0954A 50/12.5 mg~* Serum creatinine \>2 mg/dL

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- All Participants (Type: None): Participants with hypertension who had been treated with MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg) for at least three months

Based on this trial design, predict the completion outcome and termination type (if applicable).